2006•PubMedRequires access
Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Raymond M. Reilly
Open publisher page 23 citations
Abstract
Radioimmunotherapy (RIT) of malignancies has been studied for more than 2 decades ( [1][1] ). The basic premise of RIT—that monoclonal antibodies (mAbs) directed against a tumor-associated antigen can be used to target radionuclides to cancer cells for in situ radiation therapy—has been proven